GBT'un PS Oranı emsallerine kıyasla nasıldır?

GBT, Price-To-Sales değerine göre iyi bir değerdir. Eş ortalamaya (19.7x) kıyasla oran (27.8x).

GBT'nin PS Oranı, US Biotechs Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

GBT Price-To-Sales Oranı ( 19.7 x) baz alındığında, US Biotechs sektör ortalamasına ( 9.6 x) kıyasla pahalıdır.

GBT'nin PS Oranı, Adil PS Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PS Oranıdır.

GBT tahmini Adil Price-To-Sales Price-To-Sales Oranı ( 19.7 22.9 x) ile karşılaştırıldığında iyi bir değerdir.

Gelecekteki nakit akışlarına bakıldığında GBT 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

GBT ( $68.49 ) [[adil değer]] tahminimizin altında işlem görüyor ( $195.86 )

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Hedef fiyat, mevcut hisse senedi fiyatından % 20 daha az yüksektir.

Global Blood Therapeutics (Nasdaq:GBT) - Hisse Senedi Fiyatı, Haberler ve Analizler

GBT Stoklara Genel Bakış

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). Daha fazla detay

GBT temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 65% daha düşük bir oranda işlem görüyor

Kazançların yılda 66.18% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda dalgalı hisse senedi fiyatı

Global Blood Therapeutics, Inc. Rakipler

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$3.6b

Alvotech

NasdaqGM:ALVO

US$3.7b

Apellis Pharmaceuticals

NasdaqGS:APLS

US$3.4b

ADMA Biologics

NasdaqGM:ADMA

US$5.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Global Blood Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$68.49
52 Haftanın En Yüksek Seviyesi	US$73.02
52 Haftanın En Düşük Seviyesi	US$21.65
Beta	0.46
11 Aylık Değişim	1.02%
3 Aylık Değişim	98.98%
1 Yıllık Değişim	169.54%
33 Yıllık Değişim	45.26%
5 Yıllık Değişim	106.30%
Halka arzdan bu yana değişim	58.87%

Son Haberler & Güncellemeler

Global Blood Therapeutics expects to complete Pfizer deal in early October

Sep 30

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

Sep 16

Recent updates

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Jul 14

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Jun 29

Global Blood Therapeutics: Powerhouse Of The Future

Jun 21

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Jun 07

Global Blood Therapeutics: Hitting A Growth Inflection

Apr 12

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Mar 12

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Feb 24

Global Blood Therapeutics: Revisiting A Stellar Grower

Dec 25

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Nov 30

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Nov 03

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Oct 24

Global Blood Therapeutics: Attempting To Classify The Investment

Aug 07

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jul 08

Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Jun 12

Global Blood Therapeutics announces employment inducement grants

Jun 04

Global Blood Therapeutics: Increasing Specialization In SCD

May 09

Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Mar 18

Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Feb 20

Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?

Jan 25

Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?

Dec 29

Hissedar Getirileri

	GBT	US Biotechs	US Pazar
7D	0.6%	-3.7%	0.3%
1Y	169.5%	15.2%	31.1%

Getiri vs. Endüstri: GBT geçen yıl % 15.2 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: GBT geçen yıl % 31.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is GBT's price volatile compared to industry and market?
GBT volatility
GBT Average Weekly Movement	15.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: GBT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: GBT 'nin haftalık oynaklığı ( 15% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	457	Ted Love	www.gbt.com

Global Blood Therapeutics, Inc. Temel Bilgiler Özeti

Global Blood Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
GBT temel i̇stati̇sti̇kler
Piyasa değeri	US$4.62b
Kazançlar(TTM)	-US$322.46m
Gelir(TTM)	US$234.86m

19.7x

P/S Oranı

-14.3x

F/K Oranı

GBT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
GBT gelir tablosu (TTM)
Gelir	US$234.86m
Gelir Maliyeti	US$4.45m
Brüt Kâr	US$230.41m
Diğer Giderler	US$552.87m
Kazançlar	-US$322.46m

Son Raporlanan Kazançlar

Jun 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.78
Brüt Marj	98.10%
Net Kâr Marjı	-137.30%
Borç/Özkaynak Oranı	491.7%

GBT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

GBT Stoklara Genel Bakış

Ödüller

Risk Analizi

Global Blood Therapeutics, Inc. Rakipler

NasdaqGM:RYTM

US$3.6b

NasdaqGM:ALVO

US$3.7b

NasdaqGS:APLS

US$3.4b

NasdaqGM:ADMA

US$5.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

Executive Vice President of Operations exercised options to buy US$2.0m worth of stock.

Global Blood Therapeutics expects to complete Pfizer deal in early October

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

Recent updates

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

Executive Vice President of Operations exercised options to buy US$2.0m worth of stock.

Global Blood Therapeutics expects to complete Pfizer deal in early October

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

CFO & Principal Accounting Officer notifies of intention to sell stock

Pfizer said to have had bidding war with Johnson & Johnson for Global Blood

Executive Vice President of Operations recently sold US$314k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Price target increased to US$66.03

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics

Pfizer Reportedly in Advanced Talks to Buy Global Blood Therapeutics for $5 Billion

CFO & Principal Accounting Officer exercised options and sold US$69k worth of stock

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MHRA Grants Marketing Authorization for Global Blood Therapeutics, Inc.'s Oxbryta (Voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Global Blood Therapeutics, Inc. Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Independent Director notifies of intention to sell stock

Global Blood Therapeutics: Powerhouse Of The Future

Global Blood Therapeutics, Inc. Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (Voxelotor) in Sickle Cell Disease

Global Blood Therapeutics, Inc.'s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Blood Therapeutics: Hitting A Growth Inflection

Chief Commercial Officer exercised options and sold US$54k worth of stock

No longer forecast to breakeven

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Consensus EPS estimates fall by 23%

Full year 2021 earnings: EPS exceeds analyst expectations

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

Global Blood Therapeutics, Inc. Announces Positive Early Access to Medicines Scheme Scientific Opinion

Global Blood Therapeutics, Inc. announces Oxbryta® (voxelotor) tablets for oral suspension

Forecast to breakeven in 2024

Global Blood Therapeutics: Revisiting A Stellar Grower

Global Blood Therapeutics, Inc. Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

Global Blood Therapeutics, Inc. Presents Positive Results from Phase 1 Study of Gbt021601 in Patients with Sickle Cell Disease and Healthy Volunteers At ASH Annual Meeting and Exposition

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Chief Commercial Officer exercised options and sold US$57k worth of stock

Independent Director recently sold US$145k worth of stock

Global Blood Therapeutics, Inc. Announces the U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for Oxbryta (Voxelotor)

President exercised options and sold US$140k worth of stock

Global Blood Therapeutics: Attempting To Classify The Investment

Second quarter 2021 earnings released: US$1.12 loss per share (vs US$0.86 loss in 2Q 2020)

CFO & Principal Accounting Officer exercised options and sold US$119k worth of stock

Global Blood Therapeutics, Inc. Provides Regulatory and Pipeline Updates in Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell Midcap Growth Index